, Volume 39, Issue 2, pp 117–127 | Cite as

A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs

  • Silvan R. Urfer
  • Tammi L. Kaeberlein
  • Susan Mailheau
  • Philip J. Bergman
  • Kate E. Creevy
  • Daniel E. L. Promislow
  • Matt KaeberleinEmail author
Original Article


Age is the single greatest risk factor for most causes of morbidity and mortality in humans and their companion animals. As opposed to other model organisms used to study aging, dogs share the human environment, are subject to similar risk factors, receive comparable medical care, and develop many of the same age-related diseases humans do. In this study, 24 middle-aged healthy dogs received either placebo or a non-immunosuppressive dose of rapamycin for 10 weeks. All dogs received clinical and hematological exams before, during, and after the trial and echocardiography before and after the trial. Our results showed no clinical side effects in the rapamycin-treated group compared to dogs receiving the placebo. Echocardiography suggested improvement in both diastolic and systolic age-related measures of heart function (E/A ratio, fractional shortening, and ejection fraction) in the rapamycin-treated dogs. Hematological values remained within the normal range for all parameters studied; however, the mean corpuscular volume (MCV) was decreased in rapamycin-treated dogs. Based on these results, we will test rapamycin on a larger dog cohort for a longer period of time in order to validate its effects on cardiac function and to determine whether it can significantly improve healthspan and reduce mortality in companion dogs.


Dogs Cardiac aging Rapamycin Echocardiogram Blood chemistry Healthspan Sirolimus 



We would like to thank Dr. Karen Kline and Dr. Heidi MacLean for clinical veterinary support. This work was partially supported by the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging (NIH Grant P30AG013280). SU was supported by donations from the Irish Wolfhound Association of New England and the Donner Foundation to the Dog Aging Project. DP and KC received support from NIH Grant R24AG044284.

Compliance with ethical standards

All procedures were approved by the University of Washington Institutional Animal Care and Use Committee (IACUC) under protocol number 4359-02. All of the owners completed a written informed consent prior to their first study-related veterinary visit.

Supplementary material

11357_2017_9972_MOESM1_ESM.pdf (257 kb)
ESM 1 (PDF 256 kb)


  1. Alexandre J, Raymond E, Armand JP (1999) Rapamycin and CCI-779. Bull Cancer 86(10):808–811PubMedGoogle Scholar
  2. Anisimov VN et al (2011) Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10(24):4230–4236CrossRefPubMedGoogle Scholar
  3. Bitto A et al (2016) Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. elife 5:e16351CrossRefPubMedPubMedCentralGoogle Scholar
  4. Boers-Doets CB et al (2013) Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 9(12):1883–1892CrossRefPubMedGoogle Scholar
  5. Brattstrom C et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65(9):1272–1274CrossRefPubMedGoogle Scholar
  6. Chen C, Liu Y, Zheng P (2009) mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2(98):ra75CrossRefPubMedPubMedCentralGoogle Scholar
  7. Cohen E (2016) This pill could make your dog (and maybe you) live longer. (CNN)Google Scholar
  8. Dai DF et al (2014) Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13(3):529–539CrossRefPubMedPubMedCentralGoogle Scholar
  9. Detweiler DK, Patterson DF (1965) The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 127(1):481–516CrossRefPubMedGoogle Scholar
  10. Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63(23):8451–8460PubMedGoogle Scholar
  11. Fischer KE et al (2015) Health effects of long-term rapamycin treatment: the impact on mouse health of enteric rapamycin treatment from four months of age throughout life. PLoS One 10(5):e0126644CrossRefPubMedPubMedCentralGoogle Scholar
  12. Flynn JM et al (2013) Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 12(5):851–862CrossRefPubMedPubMedCentralGoogle Scholar
  13. Gamaldo AA, Ferrucci L, Rifkind J, Longo DL, Zonderman AB (2013) Relationship between mean corpuscular volume and cognitive performance in older adults. J Am Geriatr Soc 61(1):84–89CrossRefPubMedPubMedCentralGoogle Scholar
  14. Gilmore KM, Greer KA (2015) Why is the dog an ideal model for aging research? Exp Gerontol 71:14–20CrossRefPubMedGoogle Scholar
  15. Halloran J et al (2012) Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 223:102–113CrossRefPubMedPubMedCentralGoogle Scholar
  16. Harrison DE et al (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460(7253):392–395PubMedPubMedCentralGoogle Scholar
  17. Johnson SC, Martin GM, Rabinovitch PS, Kaeberlein M (2013) Preserving youth: does rapamycin deliver? Sci Transl Med 5(211):211fs240CrossRefGoogle Scholar
  18. Johnson SC, Sangesland M, Kaeberlein M, Rabinovitch PS (2015) Modulating mTOR in aging and health. Interdiscip Top Gerontol 40:107–127CrossRefPubMedGoogle Scholar
  19. Jones TC, Zook BC (1965) Aging changes in the vascular system of animals. Ann N Y Acad Sci 127(1):671–684CrossRefPubMedGoogle Scholar
  20. Kaeberlein M (2013) mTOR inhibition: from aging to autism and beyond. Scientifica (Cairo) 2013:849186Google Scholar
  21. Kaeberlein M (2014) Rapamycin and aging: when, for how long, and how much? J Genet Genomics 41(9):459–463CrossRefPubMedPubMedCentralGoogle Scholar
  22. Kaeberlein M (2015) The biology of aging: citizen scientists and their pets as a bridge between research on model organisms and human subjects. Vet PatholGoogle Scholar
  23. Kaeberlein M, Rabinovitch PS, Martin GM (2015) Healthy aging: the ultimate preventative medicine. Science 350(6265):1191–1193CrossRefPubMedPubMedCentralGoogle Scholar
  24. Kaeberlein M, Creevy KE, Promislow DE (2016) The dog aging project: translational geroscience in companion animals. Mammalian genome: official journal of the International Mammalian Genome Society 27(7–8):279–288CrossRefGoogle Scholar
  25. Kealy RD et al (2002) Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 220(9):1315–1320CrossRefPubMedGoogle Scholar
  26. Kennedy BK et al (2014) Geroscience: linking aging to chronic disease. Cell 159(4):709–713CrossRefPubMedPubMedCentralGoogle Scholar
  27. Khan KH et al (2016) Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist 21(7):855–860CrossRefPubMedGoogle Scholar
  28. Lamming DW et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335(6076):1638–1643CrossRefPubMedPubMedCentralGoogle Scholar
  29. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293CrossRefPubMedPubMedCentralGoogle Scholar
  30. Larson JC et al (2016) Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res 77(1):65–71CrossRefPubMedGoogle Scholar
  31. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194–1217CrossRefPubMedPubMedCentralGoogle Scholar
  32. Majumder S et al (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11(2):326–335CrossRefPubMedPubMedCentralGoogle Scholar
  33. Mannick JB et al (2014) mTOR inhibition improves immune function in the elderly. Sci Transl Med 6(268):268ra179CrossRefPubMedGoogle Scholar
  34. Miller RA et al (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66(2):191–201CrossRefPubMedGoogle Scholar
  35. Neff MW, Rine J (2006) A fetching model organism. Cell 124(2):229–231CrossRefPubMedGoogle Scholar
  36. Neff F et al (2013) Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123(8):3272–3291CrossRefPubMedPubMedCentralGoogle Scholar
  37. Paoloni MC et al (2010) Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5(6):e11013CrossRefPubMedPubMedCentralGoogle Scholar
  38. Parikh JD, Hollingsworth KG, Wallace D, Blamire AM, MacGowan GA (2016) Normal age-related changes in left ventricular function: role of afterload and subendocardial dysfunction. Int J Cardiol 223:306–312CrossRefPubMedPubMedCentralGoogle Scholar
  39. Pitt JN, Kaeberlein M (2015) Why is aging conserved and what can we do about it? PLoS BiolGoogle Scholar
  40. Ross C et al (2015) Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY) 7(11):964–973CrossRefGoogle Scholar
  41. Sierra F, Kohanski R (2017) Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience 39(1):1–5CrossRefPubMedPubMedCentralGoogle Scholar
  42. Singh JP et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83(6):897–902CrossRefPubMedGoogle Scholar
  43. Tardif S et al (2015) Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 70(5):577–587CrossRefPubMedGoogle Scholar
  44. Team RC (2016) R: a language and environment for statistical computing. R foundation for statistical Computing, ViennaGoogle Scholar
  45. Templeton GH, Willerson JT, Platt MR, Weisfeldt M (1976) Contraction duration and diastolic stiffness in aged canine left ventricle. Recent Adv Stud Cardiac Struct Metab 11:169–173PubMedGoogle Scholar
  46. Urfer SR et al (2017) Asymptomatic heart valve dysfunction in healthy middle-aged companion dogs and its implications for cardiac aging. Geroscience 39(1):43–50CrossRefPubMedPubMedCentralGoogle Scholar
  47. Weinreich J et al (2011) Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling. Eur Surg Res 47(1):39–44CrossRefPubMedGoogle Scholar
  48. Wilkinson JE et al (2012) Rapamycin slows aging in mice. Aging Cell 11(4):675–682CrossRefPubMedPubMedCentralGoogle Scholar
  49. Xie J, Wang X, Proud CG (2016) mTOR inhibitors in cancer therapy. F1000Res 5Google Scholar
  50. Xu B & Daimon M (2016) Cardiac aging phenomenon and its clinical features by echocardiography. J EchocardiogrGoogle Scholar
  51. Yi H et al (2014) Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med 92(6):641–650CrossRefPubMedGoogle Scholar
  52. Yilmaz OH et al (2012) mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 486(7404):490–495PubMedPubMedCentralGoogle Scholar

Copyright information

© American Aging Association 2017

Authors and Affiliations

  1. 1.Department of PathologyUniversity of WashingtonSeattleUSA
  2. 2.Dog Aging ProjectSeattleUSA
  3. 3.VCA Clinical StudiesLos AngelesUSA
  4. 4.College of Veterinary MedicineTexas A&M UniversityCollege StationUSA
  5. 5.Department of BiologyUniversity of WashingtonSeattleUSA

Personalised recommendations